The Global Burden and Temporal Trends of Psoriasis, 1990–2021: Implications From the COVID‐19 Pandemic

ABSTRACT Background and Aims Psoriasis can lead to the occurrence of various chronic diseases. However, the detailed reports of psoriasis before and after COVID‐19 are limited. The present study aimed to investigate the global prevalence, incidence, and death and disability adjusted life years (DALYs) of psoriasis with age and sex differences from 1990 to 2021. Methods Data were extracted from the Global Burden of Disease (GBD) Study 2021. Our research combined multiple models such as estimated annual percentage change (EAPC), joinpoint regression (JPR), age‐period‐cohort (APC), Bayesian age‐period‐cohort (BAPC) to comprehensively and in‐depth describe the global epidemiological characteristics of psoriasis and its associations with COVID‐19 and respiratory infections. Results The ASRs of prevalence, incidence and DALYs were 516, 62, and 44.4 per 100,000 with increased change percentage, 8% (95% UI: 7.7%–8.3%), 8.8% (95% UI: 8.5%–9%) and 8% (95% UI: 7%–9%), respectively. Western Europe, Andean Latin America, and High‐income North America had highest ASRs of prevalence (1155.9, 1018.7, 975.7 per 100,000), incidence (115.3, 105, 103.5 per 100,000), and DALYs (99.8, 88.4, 83.1 per 100,000), while the most changing rate was in East Asia (30.8%, 25.6%, 31%), North Africa and Middle East (27%, 21.4%, 26.5%) and Southeast Asia (20.6%, 16.6%, 20.9%). Moreover, the annual average rate of psoriasis changed significantly before and after the COVID‐19 pandemic with different ages and sex. And the prevalence for psoriasis was negatively correlated with COVID‐19 ( R = −0.39, p < 0.001) and lower respiratory infections ( R = −0.67, p < 0.001). Finally, the trend of psoriasis will keep increasing by 2040. Conclusion The prevalence, incidence, and DALYs for psoriasis after COVID‐19 will still increase leading to a severe issue that urgently needs to be solved around world. Our present study integrated with the models and analysis will provide an important theoretical foundation for formulating measures to prevent and treat psoriasis on a global scale in the future.

Authors

Institutions

Publication Details

Journal
Health Science Reports
Published
2026-08-26
DOI
https://doi.org/10.1002/hsr2.73095
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Global Burden and Temporal Trends of Psoriasis, 1990–2021: Implications From the COVID‐19 Pandemic

Siming Yang, Minglu Xiao, Yunda Guo, Xiaobing Fu et al.
Health Science Reports
Psoriasis: Treatment and Pathogenesis
article

The Global Burden and Temporal Trends of Psoriasis, 1990–2021: Implications From the COVID‐19 Pandemic

Siming Yang, Minglu Xiao, Yunda Guo, Xiaobing Fu, Zhiyan Zhang, Kui Ma, Jie Yang
article en

Abstract

ABSTRACT Background and Aims Psoriasis can lead to the occurrence of various chronic diseases. However, the detailed reports of psoriasis before and after COVID‐19 are limited. The present study aimed to investigate the global prevalence, incidence, and death and disability adjusted life years (DALYs) of psoriasis with age and sex differences from 1990 to 2021. Methods Data were extracted from the Global Burden of Disease (GBD) Study 2021. Our research combined multiple models such as estimated annual percentage change (EAPC), joinpoint regression (JPR), age‐period‐cohort (APC), Bayesian age‐period‐cohort (BAPC) to comprehensively and in‐depth describe the global epidemiological characteristics of psoriasis and its associations with COVID‐19 and respiratory infections. Results The ASRs of prevalence, incidence and DALYs were 516, 62, and 44.4 per 100,000 with increased change percentage, 8% (95% UI: 7.7%–8.3%), 8.8% (95% UI: 8.5%–9%) and 8% (95% UI: 7%–9%), respectively. Western Europe, Andean Latin America, and High‐income North America had highest ASRs of prevalence (1155.9, 1018.7, 975.7 per 100,000), incidence (115.3, 105, 103.5 per 100,000), and DALYs (99.8, 88.4, 83.1 per 100,000), while the most changing rate was in East Asia (30.8%, 25.6%, 31%), North Africa and Middle East (27%, 21.4%, 26.5%) and Southeast Asia (20.6%, 16.6%, 20.9%). Moreover, the annual average rate of psoriasis changed significantly before and after the COVID‐19 pandemic with different ages and sex. And the prevalence for psoriasis was negatively correlated with COVID‐19 ( R = −0.39, p < 0.001) and lower respiratory infections ( R = −0.67, p < 0.001). Finally, the trend of psoriasis will keep increasing by 2040. Conclusion The prevalence, incidence, and DALYs for psoriasis after COVID‐19 will still increase leading to a severe issue that urgently needs to be solved around world. Our present study integrated with the models and analysis will provide an important theoretical foundation for formulating measures to prevent and treat psoriasis on a global scale in the future.

Health Science ReportsVol. 9(9)
Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Chinese PLA General Hospital (CN), Tissue Regeneration Systems (United States) (US), 302 Military Hospital of China (CN), The Military General Hospital of Beijing PLA (CN)
Good health and well-being
Openalex Percentile: Top 16%
Psoriasis: Treatment and Pathogenesis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.